title: The effect of intralesional 5-fluorouracil therapeutic implant (MPI 5003) for treatment of basal cell carcinoma.
abstract: BACKGROUND
  Basal cell carcinomas (BCCs) are usually treated with ablative procedures. A nonsurgical treatment alternative would be of value in selected patients.
  
  
  OBJECTIVE
  We evaluated the safety and efficacy of a new preparation for intralesional sustained-release chemotherapy with MPI 5003, 5-Fluorouracil Therapeutic Implant, for treatment of BCCs.
  
  
  METHODS
  Two doses of intralesional MPI 5003 (0.25 and 0.5 ml) were compared in a double-blind study of 20 patients with biopsy-proven BCC. One BCC per patient was treated weekly for up to 6 weeks and followed up monthly for 3 months until excisional biopsy for histologic examination. Before excision the cosmetic appearance of the test site was graded.
  
  
  RESULTS
  Eighty percent of 10 BCCs treated with 0.5 ml of MPI 5003 had histologically confirmed cures as compared with 60% of 10 tumors treated with the lower dose (0.25 ml). Cosmetic assessments before excision were typically good to excellent. No systemic side effects occurred.
  
  
  CONCLUSIONS
  Results indicate the potential of MPI 5003 for targeted local chemotherapy for BCC.
authors.affiliation: Matrix Pharmaceutical, Inc., Menlo Park, CA 94025.
authors.forename: E K
authors.initials: EK
authors.lastname: Orenberg
authors.forename: B H
authors.initials: BH
authors.lastname: Miller
authors.forename: H T
authors.initials: HT
authors.lastname: Greenway
authors.forename: J A
authors.initials: JA
authors.lastname: Koperski
authors.forename: N
authors.initials: N
authors.lastname: Lowe
authors.forename: T
authors.initials: T
authors.lastname: Rosen
authors.forename: D M
authors.initials: DM
authors.lastname: Brown
authors.forename: M
authors.initials: M
authors.lastname: Inui
authors.forename: A G
authors.initials: AG
authors.lastname: Korey
authors.forename: E E
authors.initials: EE
authors.lastname: Luck
mesh_terms: D000328:Adult; D000368:Aged; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000473:pathology; D004311:Double-Blind Method; D004337:Drug Carriers; D004343:Drug Implants; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D004337:Drug Carriers; D004343:Drug Implants; D005472:Fluorouracil